Semiautomatic Aerosol Propellant Filler 75F40126Q00231
Summary
AI-generated · Jun 11, 2026Procurement seeks a Semiautomatic Aerosol Propellant Filler for a two-stage pMDI formulation, brand-name or equal. The contract covers purchasing, delivery, installation, validation support, training, and warranty, to support FDA CDER-OTR research in advanced pharmaceutical manufacturing and inhalation drug delivery systems, using FAR Part 12/13 procedures with the FAR Revolutionary Overhaul clauses.
Bid packages include: Statement of Work, Pricing Schedule, Past Performance Reference Form, SF-18, Brand Name or Equal Compliance Matrix, Buy American Certificate, and the Solicitation Document. Proposals must address brand-name-or-equal compliance and Buy American requirements. Questions should be submitted in writing, and quotations submitted electronically, per the RFQ’s attachments.
Semiautomatic Aerosol Propellant Filler for pMDI Two-Stage Formulation Brand Name or Equal This is a Request for Quotation (RFQ) for commercial products prepared in accordance with FAR Part 12 and FAR Part 13 procedures utilizing the FAR Revolutionary FAR Overhaul clauses and provisions available at Acquisition.gov. The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Testing and Research (OTR), requires the purchase, delivery, installation, validation support, training, and warranty of a Semiautomatic Aerosol Propellant Filler for pMDI Two-Stage Formulation. The requirement supports FDA research in advanced pharmaceutical manufacturing and inhalation drug delivery systems. Please refer to the following attachments for all the pertinent details of this requirement Attachment I Statement of Work (SOW) Attachment II Pricing Schedule Attachment III Past Performance Reference Form Attachment IV SF-18 Request for Quotations Attachment V Brand Name or Equal Compliance Matrix Attachment VI Buy American Certificate Attachment VII Solicitation Document Submit all questions in writing via email to Michele.Jackson@fda.hhs.gov no later than: June 15, 2026, at 9:00 AM Eastern Time Questions received after this date may not receive a response. Submit quotations electronically to Michele.Jackson@fda.hhs.gov no later than June 22, 2026, at 11:00 AM Eastern Time Include in the Subject Line: [Company Name] 75F40126Q00231/CDER-2026-133243 Quote
From Solicitation posted on Jun 10, 2026Notice history
1-
Solicitation LATEST Posted Jun 10, 2026
Details
Award Information
Not yet awarded
Documents
7Contacts
Agency
Place of Performance
USA